A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

OncoImmunology

Volumn 2, Issue 12, 2013, Pages 1-2

  Chandramohan, Vidyalakshmi ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bispecific antibody; Brain tumors; Convection enhanced delivery; Glioma associated antigens; Pseudomonas exotoxin

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOTOXIN; RECOMBINANT IMMUNOTOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; DRUG BINDING; DRUG EFFICACY; DRUG TARGETING; EGFR GENE; GENE AMPLIFICATION; GLIOBLASTOMA; HUMAN; LIGAND BINDING; MURINE MODEL; NONHUMAN; PROTEIN EXPRESSION;

EID: 84896699784     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.26852     Document Type: Article

References (10)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/ NEJMoa043330
2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al.; Cancer Genome Atlas Research Network. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17:98-110; PMID:20129251; http://dx.doi.org/10.1016/j.ccr.2009.12.020
3. Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol 2012; 2012:480429; PMID:22400035; http://dx.doi. org/10.1155/2012/480429
4. Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res 2013; 19:4717-27; PMID:23857604; http://dx.doi.org/10.1158/1078-0432.CCR-12-3891
5. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-7; PMID:10728703
6. Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE 2nd, McLendon RE, et al. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors. Nucl Med Biol 2012; 39:23-34; PMID:21958852; http://dx.doi. org/10.1016/j.nucmedbio.2011.06.005
7. Hegi ME, Rajakannu P, Weller M. Epidermal growth factor receptor: a re-emerging target in glioblastoma. Curr Opin Neurol 2012; 25:774-9; PMID:23007009; http://dx.doi.org/10.1097/ WCO.0b013e328359b0bc
8. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 2011; 1:524-38; PMID:22145100; http://dx.doi.org/10.1158/2159-8290.CD-11-0124
9. Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol 2013; 9:977-90; PMID:23837761; http://dx.doi.org/10.2217/fon.13.47
10. Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFRblocking monoclonal antibody cetuximab. Int J Oncol 2012; 41:1029-35; PMID:22752145